Literature DB >> 7987657

Factors determining the long-term outcome of surgery for acromegaly.

I A Osman1, R A James, S Chatterjee, D Mathias, P Kendall-Taylor.   

Abstract

Seventy-nine patients with acromegaly were investigated before and after transsphenoidal adenomectomy, to determine the immediate and late outcome, the pre-operative features associated with a good result, and the accuracy of post-operative testing in predicting outcome. Pre-operative evaluation included basal growth hormone (GH), GH response to oral glucose tolerance test (OGTT), GH response to thyrotrophin-releasing hormone (TRH), tests of pituitary reserve, and pituitary scanning to assess tumour size. A few weeks after surgery, these tests were repeated. The patients were recalled for late assessment 1-13 years (median 86 months) after the operation. At the immediate postoperative testing, minimum GH after oral glucose was < or = 2 mU/l in 48.7%, < 5 mU/l in 76.3% and < 10 mU/l in 84.2%. Only 12 patients had GH > 10 mU/l. Basal GH was < or = 2 mU/l in 21%, < 5 in 59.2%, < 10 in 73.6% and < 20 in 90.8%. A minimum GH of < or = 2 mU/l during an OGTT was achieved in 67.4% of patients with intrasellar tumours, compared with 27.3% with extrasellar tumours. Basal GH and post-glucose GH correlated with the late outcome. GH response to TRH showed no correlation with outcome. IGF-1, which could not be assessed in detail, correlated with GH but was not a reliable indicator of outcome. Transsphenoidal adenomectomy is thus a very satisfactory treatment for acromegaly. Postoperative levels of basal growth hormone < 5 mU/l and post-glucose GH < or = 2 mU/l can be regarded as a biochemical cure. Postoperative radiotherapy is not required in patients who achieve a good result. The preoperative factors which significantly influenced the final outcome were basal GH, post-glucose minimum GH, tumour size and impaired pituitary reserve.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7987657

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  8 in total

1.  Pituitary surgery for acromegaly. Should be done by specialists.

Authors:  R N Clayton; P M Stewart; S M Shalet; J A Wass
Journal:  BMJ       Date:  1999-09-04

Review 2.  The importance of locating a good pituitary surgeon.

Authors:  J A Wass; H E Turner; C B Adams
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

3.  Determinants of neurosurgical outcome in pituitary tumors.

Authors:  M J Barahona; L Sojo; A M Wägner; F Bartumeus; B Oliver; P Cano; S M Webb
Journal:  J Endocrinol Invest       Date:  2005-10       Impact factor: 4.256

Review 4.  Surgery induced hypopituitarism in acromegalic patients: a systematic review and meta-analysis of the results.

Authors:  Pedro Carvalho; Eva Lau; Davide Carvalho
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

Review 5.  Epidemiology of acromegaly.

Authors:  I M Holdaway; C Rajasoorya
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

6.  The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects.

Authors:  J Gilbert; M Ketchen; P Kane; T Mason; E Baister; M Monaghan; S Barr; P E Harris
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

Review 7.  Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira
Journal:  Pituitary       Date:  2012-03       Impact factor: 4.107

8.  Surgical management of acromegaly: Long term functional outcome analysis and assessment of recurrent/residual disease.

Authors:  Deepu Banerji; Nitu K Das; Siddhiraj Sharma; Yogesh Jindal; Vijendra K Jain; Sanjay Behari
Journal:  Asian J Neurosurg       Date:  2016 Jul-Sep
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.